Emmaus Life Sciences Profit Margin

The latest profit margin for EMMA is -38.79% as of June 2026. That compares with -24.2% in the prior-year period — down 60.3% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Emmaus Life Sciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, EMMA's profit margin moved from -24.2% to -38.79% — a 60.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Emmaus Life Sciences's valuation or profitability profile.

Against Healthcare companies, EMMA currently prints -38.79% for profit margin, while the sector average sits near 21.34%. That is roughly 281.8% below the sector mean. Large gaps often invite a closer look at Emmaus Life Sciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Emmaus Life Sciences converts resources into returns. At -38.79%, EMMA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -24.2% in the prior-year period — down 60.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting EMMA's profit margin (-38.79%), review year-over-year change from -24.2%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.